Liu, Shengwu

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 468

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

Gonzalvez, F., Vincent, S., Baker, T. E., Gould, A. E., Li, S., Wardwell, S. D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.-S., et al. (2021) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 190

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell

Lung Cancer Treatments and MutationsCancer Cells and Metastasis

Cited by 142

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer

Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 67

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Han, H., Li, S., Chen, T., Fitzgerald, M., Liu, S., Peng, C., Tang, K. H., Cao, S., Chouitar, J., Wu, J., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 57

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Awad, M., Liu, S., Arbour, K., Zhu, V., Johnson, M., Heist, R., Patil, T., Riely, G., Jacobson, J., Dilly, J., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 12